C000221226 Fees and Costs — iShares Health Innovation Active ETF
Data updated: 2026-10-14
The net expense ratio is 0.55% (0.77% before fee waivers). There are no sales loads or redemption fees. In fiscal 2026 the fund paid $4K in broker commissions, 0.0464% of average net assets, and portfolio turnover was 109%.
C000221226 Fees and Expenses
Annual operating expenses and sales charges of C000221226. Prospectus, as of July 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.77% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.00% |
| Gross expense ratio | 0.77% |
| Fee waiver | −0.22% |
| Net expense ratio | 0.55% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
C000221226 Costs Over Time
On $10,000 invested in C000221226, assuming 5% a year before costs, total costs come to $376 over 5 years, cutting the return by 0.63% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.55%) | $58 | $181 | $315 |
| Trading costs (broker commissions) | $5 | $15 | $27 |
| Lost growth on money paid in costs | $0 | $10 | $34 |
| Total costs | $63 | $206 | $376 |
| Value after costs | $10,437 | $11,370 | $12,387 |
| Impact on return, per year | 0.63% | 0.63% | 0.63% |
C000221226 Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending July 31, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0464%
- Total broker commissions: $4K
- Bought from dealers (principal trades, not a cost): $14.4M
- Portfolio turnover (prospectus): 109%
C000221226 Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Morgan Stanley & Co. LLC | $719 | 22.53% |
| J.P. Morgan Securities LLC | $433 | 13.57% |
| BofA Securities, Inc. | $432 | 13.54% |
| UBS Securities LLC | $426 | 13.34% |
| Citigroup Global Markets Inc. | $328 | 10.27% |
| BNP Paribas Securities Corp. | $230 | 7.21% |
| Barclays Capital Inc. | $188 | 5.91% |
| Goldman Sachs & Co. LLC | $181 | 5.67% |
| CLSA Americas, LLC | $145 | 4.54% |
| KeyBanc Capital Markets Inc. | $109 | 3.43% |
C000221226 Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| BlackRock Funds III - BlackRock Cash Funds: Treasury | $8.2M | 57.49% |
| J.P. Morgan Securities LLC | $6.0M | 41.63% |
| Leerink Partners LLC | $52K | 0.36% |
| Jefferies LLC | $32K | 0.22% |
| Goldman Sachs & Co. LLC | $31K | 0.22% |
| Morgan Stanley & Co. LLC | $12K | 0.08% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.